tiprankstipranks
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (DE:08HH)
FRANKFURT:08HH
Germany Market

Shanghai Fosun Pharmaceutical (Group) Co (08HH) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

08HH Analyst Ratings

Strong Buy
4Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Shanghai
Fosun Pharmaceutical (Group) Co
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

08HH Stock 12 Month Forecast

Average Price Target

€3.45
▲(43.89% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Shanghai Fosun Pharmaceutical (Group) Co in the last 3 months. The average price target is €3.45 with a high forecast of €3.91 and a low forecast of €2.81. The average price target represents a 43.89% change from the last price of €2.40.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","4":"€4"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3.9102162999999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€3.91</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.453285925,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.8135833999999997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.81</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1,2,3,4],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.853,2.0112474076923075,2.169494815384615,2.327742223076923,2.4859896307692306,2.6442370384615383,2.802484446153846,2.960731853846154,3.1189792615384615,3.277226669230769,3.435474076923077,3.593721484615384,3.751968892307692,{"y":3.9102162999999996,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.853,1.9760989173076924,2.0991978346153846,2.2222967519230767,2.3453956692307694,2.4684945865384615,2.5915935038461537,2.7146924211538463,2.8377913384615385,2.9608902557692307,3.0839891730769233,3.207088090384615,3.3301870076923077,{"y":3.453285925,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.853,1.9268910307692306,2.0007820615384615,2.0746730923076924,2.148564123076923,2.2224551538461537,2.2963461846153845,2.3702372153846154,2.444128246153846,2.5180192769230767,2.5919103076923076,2.665801338461538,2.739692369230769,{"y":2.8135833999999997,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.643,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.762,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.08,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.738,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.592,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.358,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.096,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.054,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.2,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.053,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.853,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€3.91Average Price Target€3.45Lowest Price Target€2.81
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:08HH
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
€3.54
Buy
47.69%
Upside
Reiterated
06/01/26
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Receives a Buy from Morgan Stanley
CLSA Analyst forecast on DE:08HH
Unknown Analyst
CLSA
Not Ranked
CLSA
€2.81
Buy
17.23%
Upside
Reiterated
04/29/26
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Receives a Buy from CLSA
Citic Securities Analyst forecast on DE:08HH
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
€3.54
Buy
47.69%
Upside
Reiterated
04/08/26
Citic Securities Sticks to Its Buy Rating for Shanghai Fosun Pharmaceutical (Group) Co (SFOSF)
Citi Analyst forecast on DE:08HH
Unknown Analyst
Citi
Not Ranked
Citi
€3.91
Buy
62.93%
Upside
Reiterated
03/26/26
Citi Keeps Their Buy Rating on Shanghai Fosun Pharmaceutical (Group) Co (SFOSF)
CSC Financial Analyst forecast on DE:08HH
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
€2.94
Buy
22.31%
Upside
Reiterated
12/10/25
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Gets a Buy from CSC Financial
Goldman Sachs Analyst forecast on DE:08HH
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
€2.06€3.03
Hold
26.23%
Upside
Reiterated
10/31/25
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Receives a Hold from Goldman Sachs
HSBC
€2.94
Sell
22.31%
Upside
Reiterated
09/30/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on DE:08HH
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
€3.54
Buy
47.69%
Upside
Reiterated
06/01/26
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Receives a Buy from Morgan Stanley
CLSA Analyst forecast on DE:08HH
Unknown Analyst
CLSA
Not Ranked
CLSA
€2.81
Buy
17.23%
Upside
Reiterated
04/29/26
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Receives a Buy from CLSA
Citic Securities Analyst forecast on DE:08HH
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
€3.54
Buy
47.69%
Upside
Reiterated
04/08/26
Citic Securities Sticks to Its Buy Rating for Shanghai Fosun Pharmaceutical (Group) Co (SFOSF)
Citi Analyst forecast on DE:08HH
Unknown Analyst
Citi
Not Ranked
Citi
€3.91
Buy
62.93%
Upside
Reiterated
03/26/26
Citi Keeps Their Buy Rating on Shanghai Fosun Pharmaceutical (Group) Co (SFOSF)
CSC Financial Analyst forecast on DE:08HH
Unknown Analyst
CSC Financial
Not Ranked
CSC Financial
€2.94
Buy
22.31%
Upside
Reiterated
12/10/25
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Gets a Buy from CSC Financial
Goldman Sachs Analyst forecast on DE:08HH
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
€2.06€3.03
Hold
26.23%
Upside
Reiterated
10/31/25
Shanghai Fosun Pharmaceutical (Group) Co (SFOSF) Receives a Hold from Goldman Sachs
HSBC
€2.94
Sell
22.31%
Upside
Reiterated
09/30/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Shanghai Fosun Pharmaceutical (Group) Co

3 Months
Success Rate
1/2 ratings generated profit
50%
Average Return
-4.30%
Copying John Yung's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -4.30% per trade.
1 Year
Success Rate
0/2 ratings generated profit
0%
Average Return
-32.45%
Copying John Yung's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -32.45% per trade.
2 Years
Success Rate
0/2 ratings generated profit
0%
Average Return
-32.45%
Copying John Yung's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -32.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

08HH Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
1
2
2
2
Buy
2
0
1
1
1
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
1
3
3
3
In the current month, 08HH has received 3 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 08HH average Analyst price target in the past 3 months is 3.45.
Each month's total comprises the sum of three months' worth of ratings.

08HH Financial Forecast

08HH Earnings Forecast

Next quarter’s earnings estimate for 08HH is €0.05 with a range of €0.04 to €0.05. The previous quarter’s EPS was €0.04. 08HH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 08HH has Performed in-line its overall industry.
Next quarter’s earnings estimate for 08HH is €0.05 with a range of €0.04 to €0.05. The previous quarter’s EPS was €0.04. 08HH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 08HH has Performed in-line its overall industry.

08HH Sales Forecast

Next quarter’s sales forecast for 08HH is €1.35B with a range of €1.35B to €1.35B. The previous quarter’s sales results were ―. 08HH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 08HH has Performed in-line its overall industry.
Next quarter’s sales forecast for 08HH is €1.35B with a range of €1.35B to €1.35B. The previous quarter’s sales results were ―. 08HH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 08HH has Performed in-line its overall industry.

08HH Stock Forecast FAQ

What is DE:08HH’s average 12-month price target, according to analysts?
Based on analyst ratings, Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s 12-month average price target is 3.45.
    What is DE:08HH’s upside potential, based on the analysts’ average price target?
    Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 43.89% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H a Buy, Sell or Hold?
          Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has a consensus rating of Strong Buy, which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s share price target?
            The average share price target for Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H is 3.45. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €3.91 ,and the lowest forecast is €2.81. The average share price target represents 43.89% Increase from the current price of €2.4.
              What do analysts say about Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
              Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
                To buy shares of DE:08HH, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.